EPIDEMIOLOGY, TREATMENT, BIOLOGY OF JUVENILE MYELOGENOUS LEUKEMIA & MONOSOMY 7
幼年型粒细胞白血病的流行病学、治疗和生物学
基本信息
- 批准号:6280855
- 负责人:
- 金额:$ 2.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-12-01 至 1998-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This translational research proposal addresses the epidemiology, biology
and treatment of children with the related preleukemic conditions juvenile
chronic myelogenous leukemia and bone marrow monosomy 7 syndrome
(JCML/Mo7). These disorders share a number of major clinical features that
suggest they are related pathogenically; however, the precise relationship
between them is uncertain. Treatment results in children with JCML/Mo7
have been dismal even with allogeneic bone marrow transplantation. This
proposal is based upon recent epidemiological findings linking specific
obstetric and parental occupational risk factors with the development of
myeloid leukemia during infancy; upon the observation that some children
with JCML have show clinical responses to the differentiating agent cis
retinoic acid; and upon molecular genetic and biochemical studies that
implicate deregulated signaling through the p21 ras family of proteins in
the pathogenesis of these malignant myeloid disorders. We will test the
hypothesis that JCML/Mo7 are associated with genetic and acquired risk
factors which correlate with specific molecular and cytogenetic
alterations in patient bone marrows, and that these molecular markers will
be of prognostic value and can be used to measure responses to treatment.
这项转化研究提案涉及流行病学,生物学
和治疗患有相关白血病前期疾病的儿童
慢性粒细胞白血病和骨髓单体7综合征
(JCML/Mo7)。这些疾病共有许多主要的临床特征,
表明它们在致病上相关;然而,
他们之间是不确定的。JCML/Mo 7儿童的治疗结果
即使是同种异体骨髓移植也是令人沮丧的。这
这项建议是基于最近的流行病学调查结果,
产科和父母的职业危险因素与发展
婴儿期的骨髓性白血病;观察到一些儿童
与JCML显示临床反应分化剂顺式
视黄酸;以及分子遗传学和生物化学研究,
暗示通过p21 ras蛋白家族的信号失调,
这些恶性骨髓疾病的发病机制。我们将测试
假设JCML/Mo 7与遗传和获得性风险相关
与特定分子和细胞遗传学相关的因素
患者骨髓的改变,这些分子标记物将
具有预后价值,并可用于测量对治疗的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN M. SHANNON其他文献
KEVIN M. SHANNON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN M. SHANNON', 18)}}的其他基金
In Vivo Functional Analysis of Chromosome 7q22 Deletions in Myeloid Malignancies
骨髓恶性肿瘤中染色体 7q22 缺失的体内功能分析
- 批准号:
9924474 - 财政年份:2017
- 资助金额:
$ 2.39万 - 项目类别:
Selectively Targeting Oncogenic NRAS in Cancer
选择性靶向癌症中的致癌 NRAS
- 批准号:
10372214 - 财政年份:2015
- 资助金额:
$ 2.39万 - 项目类别:
Project 3: Efficacy of MEK Inhibition in Juvenile Myelomonocytic Leukemia
项目3:MEK抑制对幼年粒单核细胞白血病的疗效
- 批准号:
8932164 - 财政年份:2015
- 资助金额:
$ 2.39万 - 项目类别:
Selectively Targeting Oncogenic NRAS in Cancer
选择性靶向癌症中的致癌 NRAS
- 批准号:
10209682 - 财政年份:2015
- 资助金额:
$ 2.39万 - 项目类别:
Selectively Targeting Oncogenic NRAS in Cancer
选择性靶向癌症中的致癌 NRAS
- 批准号:
9040123 - 财政年份:2015
- 资助金额:
$ 2.39万 - 项目类别:
Selectively Targeting Oncogenic NRAS in Cancer
选择性靶向癌症中的致癌 NRAS
- 批准号:
10610346 - 财政年份:2015
- 资助金额:
$ 2.39万 - 项目类别:
相似海外基金
Urinary Phthalate Biomarker Concentrations and Breast and Prostate Cancer Risk in a National Cohort of Adults in Canada
加拿大全国成人队列中尿液邻苯二甲酸盐生物标志物浓度与乳腺癌和前列腺癌风险
- 批准号:
494953 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Operating Grants
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders
深度学习图像分析算法可改善口腔潜在恶性疾病的口腔癌风险评估
- 批准号:
10805177 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Prospective metabolomics investigation of gastric cancer risk in African Americans and European Whites with a low socioeconomic status
社会经济地位较低的非裔美国人和欧洲白人胃癌风险的前瞻性代谢组学调查
- 批准号:
10912190 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Developing diagnostics of patient-specific cancer risk and early-stage tumorigenesis
开发患者特异性癌症风险和早期肿瘤发生的诊断方法
- 批准号:
478999 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Operating Grants
Environmental Metal Exposures and Breast Cancer Risk: A Prospective Study of Nationally Representative Canadian Data
环境金属暴露与乳腺癌风险:加拿大全国代表性数据的前瞻性研究
- 批准号:
495159 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Mechanisms of tamoxifen-associated endometrial cancer risk
他莫昔芬相关子宫内膜癌风险的机制
- 批准号:
10650054 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Gut microbiota-related mechanisms that impact colorectal cancer risk after bariatric surgery
影响减肥手术后结直肠癌风险的肠道微生物相关机制
- 批准号:
10733566 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Obesity, body fat distribution, and breast cancer risk: is visceral fat the culprit after menopause?
肥胖、身体脂肪分布和乳腺癌风险:内脏脂肪是绝经后的罪魁祸首吗?
- 批准号:
10586626 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:
Optimization of a personalized skin cancer risk intervention for at-risk young adults
针对高危年轻人的个性化皮肤癌风险干预措施的优化
- 批准号:
10582944 - 财政年份:2023
- 资助金额:
$ 2.39万 - 项目类别:














{{item.name}}会员




